Results for tag: "Eylea"

Eylea is a cardiovascular drug used to treat a variety of conditions, including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. It is a recombinant human monoclonal antibody fragment that works by inhibiting the activity of vascular endothelial growth factor (VEGF). This helps to reduce the growth of abnormal blood vessels in the eye, which can lead to vision loss. Eylea is administered as an intravitreal injection, and is typically given every four to eight weeks. The Eylea market is highly competitive, with a number of companies offering similar products. These companies include Regeneron Pharmaceuticals, Novartis, Allergan, and Bayer. Each company has its own unique approach to the market, with different pricing strategies and product offerings. As such, the market is constantly evolving, with new products and strategies being developed to meet the needs of patients. Show Less Read more